Skip to main content
Pharmicell Co.,Ltd. logo

Pharmicell Co.,Ltd. — Investor Relations & Filings

Ticker · 005690 ISIN · KR7005690003 KO Manufacturing
Open in API
Filings indexed 275 across all filing types
Latest filing 2022-03-15 Proxy Solicitation & In…
Country KR South Korea
Listing KO 005690

About Pharmicell Co.,Ltd.

https://www.pharmicell.com/eng/

Pharmicell Co., Ltd. is a biopharmaceutical company specializing in stem cell technology and advanced bio-based materials. The company is a pioneer in regenerative medicine, having developed Hearticellgram-AMI, the world's first approved stem cell therapy for acute myocardial infarction. Its core business includes the development of stem cell therapeutics, a stem cell banking service for adult and cord blood cells, and a line of cosmetics based on stem cell culture media. A significant division focuses on fine chemicals, manufacturing and supplying critical raw materials for the pharmaceutical industry, such as nucleosides, mPEGs, and oligonucleotides for gene therapies. The company also produces eco-friendly flame retardants for industrial use.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Convocation of General Meeting of Shareholders' (주주총회소집공고) for Pharmicell Co., Ltd. It includes the meeting agenda, date, location, and detailed financial statements (balance sheet, income statement, etc.) as reference materials for shareholders to review before the meeting. This type of document is standard for proxy solicitation and providing information to shareholders regarding upcoming meetings, which falls under the Proxy Solicitation & Information Statement category.
2022-03-15 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Solicitation of Proxy/Proxy Statement) and contains information regarding the company's upcoming Annual General Meeting (AGM), including agenda items, financial statements for approval, and instructions for shareholders to exercise their voting rights via proxy or electronic voting. This document is a standard proxy solicitation material used to request shareholder votes for an AGM.
2022-03-15 Korean
사업보고서 (2021.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Pharmicell Co., Ltd. (파미셀 주식회사) covering the fiscal years 2020 and 2021. It includes the independent auditor's opinion, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. It is not an Annual Report (10-K) as it lacks the comprehensive management discussion and analysis (MD&A) and business overview typical of a full 10-K, and it is not an announcement (RPA) because it contains the full financial data and audit opinion. FY 2021
2022-03-15 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Pharmicell regarding the adjustment of the conversion price for convertible bonds due to a decline in market price. This type of disclosure, which details changes to capital structure instruments like convertible bonds, falls under the category of capital and financing updates.
2022-03-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Supervisory Service in South Korea. This type of filing is required when an individual or entity acquires a significant stake (typically 5% or more) in a publicly traded company, often referred to as a '5% rule' filing. In the provided taxonomy, this corresponds to a 'Major Shareholding Notification'.
2022-03-07 Korean
최대주주등소유주식변동신고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) filed by Pharmicell. It details specific share transactions (purchases) by individuals related to the company (major shareholders and executives). This falls under the category of 'Director's Dealing' (DIRS) as it reports personal share transactions by company insiders and related parties.
2022-03-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.